Resource allocation to brain research in Switzerland

Swiss Medical Weekly

Volumn 138, Issue 23-24, 2008, Pages 335-339

  Jäger, Matthias ^a,e   Lekander, I ^b   Sobocki, P ^b,c   Schwab, M E ^d   Rossler, W ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b European Health Economics   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d University of Zurich Brain Research Institute   (Switzerland)

^e UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

Brain disorders; Brain research; Cost benefit; Funding; Switzerland

Indexed keywords

ARTICLE; BRAIN DISEASE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG INDUSTRY; EUROPE; FUNDING; GEOGRAPHIC DISTRIBUTION; MEDICAL RESEARCH; RESOURCE ALLOCATION; SWITZERLAND;

EID: 46049110101     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Olesen J, Leonardi M. The burden of brain diseases in Europe. Eur J Neurol. 2003;10:471-7.
2. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12 (Suppl1):1-27.
3. Jäger M, Sobocki P, Rossler W. Cost of disorders of the brain in Switzerland. With a focus on mental disorders. Swiss Med Wkly. 2008;138:4-11.
4. Sobocki P, Lekander I, Berwick S, Olesen J, Jönsson B. Resource Allocation to Brain Research in Europe. Eur J Neurosci. 2006;24(10):2691-3.
5. CMR: The 2005/2006 CMR International R&D Factbook InSurrey, Centre for Medicines Research International (CMR), 2006.
6. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-85.
7. EFPIA: The Pharmaceutical Industry in Figures. In, European Federation of Pharmaceutical Industries and Associations (EFPIA), 2006.
8. Braintrack: Braintrack University Index Europe. In, Braintrack, 2006.
9. NIH: Estimates of Funding for Various Diseases, Conditions, Research Areas (last updated sept 21, 2005). In, National Institutes of Health (NIH) 2005.
10. Eurostat: First preliminary results: Research & Development in the EU. In, Eurostat, 2005.
11. Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet. 2006;367:1319-27.
12. Olesen J, Lekander I, Sobocki P. Resource allocation to brain research in Denmark: an example for other European countries. Eur J Neurol. 2007;14:667-71.
13. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharm. 2005;15:399-409.